Efficacy News and Research

RSS
BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

STAAR Surgical third quarter total net sales increases 6% to $13.2 million

STAAR Surgical third quarter total net sales increases 6% to $13.2 million

ISTA third quarter net revenue increases 31% to $42.0 million

ISTA third quarter net revenue increases 31% to $42.0 million

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

NPS third quarter net loss increases to $15.7 million

NPS third quarter net loss increases to $15.7 million

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial

Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Study explains statistical link between low aerobic exercise capacity and common diseases

Study explains statistical link between low aerobic exercise capacity and common diseases

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

FDA selects Rochester to lead initiative to identify improved pain treatments

FDA selects Rochester to lead initiative to identify improved pain treatments

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.